Genmab A/S (OTCMKTS:GNMSF) Sees Large Volume Increase – What’s Next?

Genmab A/S (OTCMKTS:GNMSF) shares saw unusually-high trading volume on Friday . Approximately 89,936 shares were traded during mid-day trading, an increase of 3,817% from the previous session’s volume of 2,296 shares.The stock last traded at $325.00 and had previously closed at $313.60.

Genmab A/S Stock Up 3.6%

The stock’s 50 day moving average price is $307.18 and its two-hundred day moving average price is $264.26. The firm has a market capitalization of $21.47 billion, a price-to-earnings ratio of 13.85 and a beta of 0.88.

Genmab A/S (OTCMKTS:GNMSF) last posted its quarterly earnings results on Thursday, November 6th. The company reported $6.46 earnings per share for the quarter, topping analysts’ consensus estimates of $4.86 by $1.60. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1 billion. Genmab A/S had a return on equity of 23.98% and a net margin of 41.36%.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.